Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 12/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31366709 | 0.81 | EPHX1 (0.56) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5263263 | 0.81 | EPHX1 (0.41) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5263260 | 0.81 | EPHX1 (0.41) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30035740 | 0.80 | EPHX1 (0.59) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30034737 | 0.78 | EPHX1 (0.52) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21378960 | 0.78 | POLB (0.48) | EPHX1EPHX2ALDH1A1 | |
| SCHEMBL15277631 | 0.77 | EPHX1 (0.94) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15277551 | 0.77 | EPHX1 (0.94) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11046265 | 0.77 | EPHX1 (0.94) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11046261 | 0.77 | EPHX1 (0.94) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | EPHX1 629/4885EPHX2 959/4885NPC1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.